Tumor Type

South Korea
Breast Cancer - Very young women
Project Profile
Funding Organizations
Research Organizations
Research Activities
Publication Policy

1:   Template Letters to Facilitate Communications HTML 
to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors
2:   ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML 
Clinic & Pathology

South Korea: Research Institute and Hospital, National Cancer Center Korea

Details to follow

Sequencing & Analysis

South Korea: DNA Link

Sequencing of patient’s samples is performed by DNAlink.Co.
Bioinformatic analysis of sequencing data is performed in collaboration with research team of NCC Korea and DNAlink.

Complementary Studies

South Korea: Green Cross Genome

Germline mutation of BRCA1/BRCA2 is examined by Green Cross Genome.

Data Storage, Analysis & Management

South Korea: National Cancer Center Korea
DNA Link

Details to follow

Project Summary

This project will focus on sequencing of breast cancer from young age cancer patients characterized by age at diagnosis under 35. According to our national cancer statistics for the incidence, the overall age-standardized incidence rate of cancers among very young adults (<30) in Korea was about 280 per million (Moon et al., “Cancer Incidence and Survival among Adolescents and Young Adults in Korea"). Based on the incidence rate by Korean National Cancer Incidence Database, breast cancer is the most common solid tumors among young adults aged 15-34 excepting thyroid cancer (Cancer statistics in Korea (2012) ). Cancer patients in early 20-30s are becoming an object of public concern in Korea. Breast cancers in young women will be different in clinical and genetic features and disease progression. National cancer center in Korea are collecting more than 100 tumor specimens from breast cancer patients aged 20-34. It is fundamental to analyze different genomic characteristics in early-onset tumors to identify potent driver mutations and therapeutic targets.

Principal Investigators

• Eun Sook Lee, MD, PhD

Lead Jurisdiction